{"id":668704,"date":"2023-09-19T19:56:01","date_gmt":"2023-09-19T19:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=668704"},"modified":"2023-09-19T19:56:01","modified_gmt":"2023-09-19T19:56:01","slug":"hereditary-transthyretin-amyloidosis-hattr-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-alnylam-ionis-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-transthyretin-amyloidosis-hattr-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-alnylam-ionis-novo-nordisk_668704.html","title":{"rendered":"Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, Ionis, Novo Nordisk"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, Ionis, Novo Nordisk\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, Ionis, Novo Nordisk\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Hereditary Transthyretin Amyloidosis (hATTR) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Hereditary Transthyretin Amyloidosis Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Hereditary Transthyretin Amyloidosis Pipeline report embraces in-depth commercial, regulatory, and Hereditary Transthyretin Amyloidosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Hereditary Transthyretin Amyloidosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the <strong>emerging therapies for Hereditary Transthyretin Amyloidosis treatment<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different <strong>Hereditary Transthyretin Amyloidosis therapies<\/strong> segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the <strong>major Hereditary Transthyretin Amyloidosis companies i<\/strong>nvolved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the <strong>Hereditary Transthyretin Amyloidosis drugs<\/strong> that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Hereditary Transthyretin Amyloidosis therapeutic market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/45788af362d08808fda57faeecf8b4b8.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hereditary Transthyretin Amyloidosis (hATTR) Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Since TTR protein is mainly produced in the liver, transplanting a new liver should almost eliminate the production of variant protein and further halt the disease progression outside the brain and eyes. Orthotopic liver transplant (OLT) is an established option for patients with early-stage disease; however, it might not eliminate the progression of the disease, because TTR produced by the transplanted liver can accumulate on the preexisting deposits. The other limitations of OLT include limited organ availability, surgical morbidity, and mortality, the need for lifelong immunosuppression, and the high cost of liver transplantation.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Recently few drugs have been approved for the treatment of hATTR. The approved therapies include inotersen (Tegsedi), patisiran (Onpattro), tafamidis meglumine (Vyndaqel), and tafamidis (Vyndamax).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Hereditary Transthyretin Amyloidosis (hATTR). Currently, <strong>Alnylam Pharmaceuticals <\/strong>is leading the therapeutics market with its Hereditary Transthyretin Amyloidosis (hATTR) drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hereditary Transthyretin Amyloidosis (hATTR) Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alnylam Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ionis Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eidos Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intellia Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Corino Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novo Nordisk<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Hereditary Transthyretin Amyloidosis (hATTR) Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vutrisiran: Alnylam Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AKCEA-TTR-LRx: Ionis Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Hereditary Transthyretin Amyloidosis Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Hereditary Transthyretin Amyloidosis Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hereditary Transthyretin Amyloidosis (hATTR) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Hereditary Transthyretin Amyloidosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Hereditary Transthyretin Amyloidosis Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Hereditary Transthyretin Amyloidosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Hereditary Transthyretin Amyloidosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Hereditary Transthyretin Amyloidosis Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Hereditary Transthyretin Amyloidosis Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Hereditary Transthyretin Amyloidosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Hereditary Transthyretin Amyloidosis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Hereditary Transthyretin Amyloidosis Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Hereditary Transthyretin Amyloidosis Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Hereditary Transthyretin Amyloidosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Hereditary Transthyretin Amyloidosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Hereditary Transthyretin Amyloidosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\">Migraine Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Migraine Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Migraine market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Migraine market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hereditary-transthyretin-amyloidosis-hattr-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-alnylam-ionis-novo-nordisk\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hereditary-transthyretin-amyloidosis-hattr-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-alnylam-ionis-novo-nordisk\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Hereditary Transthyretin Amyloidosis (hATTR) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-transthyretin-amyloidosis-hattr-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-alnylam-ionis-novo-nordisk_668704.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-668704","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/668704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=668704"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/668704\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=668704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=668704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=668704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}